Although long-term survival for people with eosinophilic granulomatosis with polyangiitis (EGPA) has improved in Japan, the introduction of Nucala (mepolizumab) as a treatment for the disease may not, on its own, have had a significant effect. That’s according to a real-world study that analyzed data from 87 EGPA…